Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Hong Kong IPOs broke its hot streak after Sciclone Pharmaceuticals (6600 HK) and Cheerwin (6601 HK) recent poor debut. But the pipeline continues to build up and quite a number of them were secondary listings. There were news reports of Xpeng (XPEV US), NIO Inc (NIO US), Li Auto Inc. (LI US), Hutchison China MediTech Ltd (HCM US) preparing for their Hong Kong secondary listing. Meanwhile Bilibili Inc (BILI US)'s HK listing was approved, Baidu (BIDU US) launched this week and Autohome Inc (Adr) (ATHM US) will trade on Monday.
We also covered other upcoming Hong Kong IPOs like Chaoju Eye Care Holdings (CEC HK), Shanghai HeartCare Medical Technology (HMT HK) and Linklogis (LINK HK) in:
Meanwhile, Coupang (CPNG US) had a spectacular debut even after pricing above its revised priced range. At this price level, valuation is expensive compared to peers and with tiered lock-up expiry, it's probably wise to lighten up from a short-term trading perspective.
For upcoming IPOs, Ximalaya FM and Waterdrop has filed confidentially for up to US$1bn and US$500m IPO, respectively. We continued our coverage of Tuya Inc (1869782D US) with peer analysis and share our thoughts on forecast, and valuation and initiation on Zhihu Technology (ZH US)
In Singapore, Aztech Global (AZTECH SP) had a less than ideal debut. The company's share price opened 7% higher but traded down to close just 0.8% above its IPO price.
Last, but not least, India ECM has been picking up momentum with a handful of IPOs launched this week. Sumeet Singh covered Kalyan Jewellers (KALYAN IN) with updates on valuation and financials since the draft prospectus.
We covered one Hong Kong placement this week. But more importantly, shareholders of IDP Education (IEL AU) have confirmed that they will be looking to sell their shares before the end of year which will be a large block:
Our overall accuracy rate is 74.1% for IPOs and 67.4% for Placements
(Performance measurement criteria is explained at the end of the note)
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.